50 results about "Streptococcal M protein" patented technology

The invention discloses a porcine reproductive and respiratory syndrome virus M protein antigen epitope peptide and a monoclonal antibody thereof. The amino acid sequence of the antigen epitope peptide is as shown in SEQ ID No. 11; the heavy chain variable region of the monoclonal antibody comprises CDR1-3 as shown in SEQ ID No.1 to SEQ ID No.3; the light chain variable region comprises CDR1-3 as shown in SEQ ID No. 4 to 6; the monoclonal antibody reacts with a plurality of PRRSV strains such as HP-PRRSV, NADC30PRRSV, NADC34PRRSV and the like, and the conservative property is good; the antibody can be obtained by biological means such as conventional genetic engineering, and the problem that the genetic sequence of the antibody is easy to lose due to long-term cryopreservation of traditional hybridoma cells is avoided; optimization of the antibody on the gene or protein level is facilitated, and the specificity and affinity of the antibody are further improved.

The invention provides a PDCoV virus mRNA (messenger Ribonucleic Acid) vaccine capable of self-cleaving and expressing a plurality of virus structural proteins and a preparation method of the PDCoV virus mRNA vaccine, and the vaccine comprises mRNA for expressing S, M and N proteins of a PDCoV virus and LNP for encapsulating the mRNA, and the LNP is marked as SMN-mRNA-LNP. The invention provides a PDCoV mRNA vaccine strategy based on combination of S, M and N for the first time, the S, M and N structural proteins of the PDCoV are connected by using a self-cleavage peptide P2A, the S protein is subjected to double proline mutation, so that a single mRNA can express multiple PDCoV antigens, and a multi-level defense system is constructed by using the neutralizing antibody induction capability of the S protein, the immune regulation function of the M protein and the cellular immune activation characteristic of the N protein. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea is provided for development of broad-spectrum and efficient PDCoV vaccines, and a practical basis is provided for research and development of coronavirus multi-antigen mRNA vaccines.

The invention discloses a porcine reproductive and respiratory syndrome virus RNA vaccine and application thereof, and relates to the technical field of veterinary biological products. According to the present invention, the coding sequence of the porcine reproductive and respiratory syndrome virus GP5 protein is optimized, and the GP5 protein is connected with the M protein through the connecting peptide, such that the saRNA prepared by using the nucleic acid molecule can produce the efficient expression on the GP5 protein and the M protein after the cell transfection. After the optimized porcine reproductive and respiratory syndrome GP5 protein and M protein fusion protein is immunized, the level of neutralizing antibodies generated by animals can be improved, and the effect of preventing the porcine reproductive and respiratory syndrome virus is achieved. Therefore, the nucleic acid molecule provided by the invention can be used for developing or preparing nucleic acid vaccines. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

The invention belongs to the technical field of in-vitro detection, and particularly relates to a method and a kit for detecting M protein in a sample. According to the kit for detecting or typing the M protein in the sample and the detection method provided by the invention, the problem of carrying out accurate qualitative and typing on the low-abundance M protein in the sample to be detected is solved; the detection method provided by the invention is higher in sensitivity, better in accuracy, simpler to operate and easier to realize automation, and does not have the subjectivity problem of manual interpretation; compared with other mass spectrometry methods, such as a liquid chromatography-tandem mass spectrometry method, the detection cost is lower, the operation is simpler, automation is easier to realize, the detection flux is higher, and popularization in clinical diagnosis and treatment is easier to realize.

The invention discloses a construction method and application of a rabies virus RNA polymerase dual-luciferase report system, and belongs to the technical field of biology. In order to solve the technical problem that a report system for detecting the RABV RNA polymerase activity needs to be developed urgently, a Firefly luciferase fragment and a vector pcDNA3.1-SRV9-M-G obtained by amplifying M protein and G protein-deleted rabies virus SRV9 strain full-length plasmid are seamlessly connected, a recombinant luciferase report plasmid is constructed, the recombinant luciferase report plasmid and an auxiliary plasmid are combined, and the recombinant luciferase RNA polymerase activity detection system is constructed. And the RABV RNA polymerase dual-luciferase report system is formed by the Renilla luciferase report plasmid and the T7 promoter plasmid, and the RABV RNA polymerase dual-luciferase report system comprises the Renilla luciferase report plasmid and the T7 promoter plasmid. The system can accurately and efficiently detect the activity of RABV polymerase, and by virtue of the function, effective antiviral targets and therapeutic drugs can be screened out in an assisted manner.

The application provides a PDCoV virus mRNA vaccine which can be self-cleaved and expresses multiple virus structure proteins and a preparation method thereof, the vaccine comprises mRNA for expressing PDCoV virus S, M and N proteins, and LNP for encapsulating the mRNA, denoted as SMN-mRNA-LNP. The application firstly proposes a PDCoV mRNA vaccine strategy based on S, M and N combination, connects three structure proteins of PDCoV S, M and N by using a self-cleaving peptide P2A, mutates the S protein with double proline, enables a single mRNA to express multiple PDCoV antigens, and utilizes the neutralizing antibody induction ability of the S protein, the immune regulation function of the M protein and the cell immune activation characteristics of the N protein to construct a multi-level defense system. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea for developing a broad-spectrum and high-efficiency PDCoV vaccine is provided, and practical basis for research and development of a coronavirus multi-antigen mRNA vaccine is provided.

This application discloses a circular RNA vaccine against porcine reproductive and respiratory syndrome (PRRS) virus, its construction method, and its application. The circular RNA vaccine comprises circular RNA and a pharmaceutically acceptable carrier. The coding elements in the circular RNA encode the GP4, GP2, GP5, and M proteins of PRRS virus. The circular RNA vaccine exhibits high stability and good safety, producing no adverse reactions after immunization of pigs. It induces high levels of neutralizing antibodies in pigs after immunization and activates a high level of cellular immune response, providing up to 100% immunoprotection. Furthermore, its preparation process eliminates the need for virus isolation, significantly shortening the research and development cycle. The production process is not constrained by biological factors such as virus titer, facilitating standardization and large-scale production, and effectively reducing production costs.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

The invention relates to a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection method for streptococcus equi subsp. Zooepidemicus virulent strains causing swine streptococcosis, and belongs to the technical field of bacterial detection. The invention provides a primer probe group which can be used for simultaneously detecting M protein variable region genes (szm-variant) of streptococcus equi subsp.zooepidemicus, conserved genes (comB) in subsp.zooepidemicus and central nervous system infection related virulence genes (bifA) of streptococcus equi subsp.zooepidemicus through Taqman probe triple fluorescent quantitative PCR (Polymerase Chain Reaction), and is shown as SEQ ID NO.1-9 in a sequence table. The multiplex fluorescent quantitative PCR detection method for the streptococcus equi subsp. Zooepidemicus virulent strain causing the swine streptococcosis can complete nucleic acid amplification and result judgment within 1 hour. According to the detection method, the amplification result is judged through the threshold cycle number (Ct value), electrophoresis detection is not needed, and the problems of pollution, false positive and the like of an amplification product can be avoided. The detection method provided by the invention has the characteristics of simplicity, convenience and rapidness in operation, high specificity, high sensitivity and good stability.

Provided is a pharmaceutical preparation, the pharmaceutical preparation comprising: a nucleic acid fragment, the nucleic acid fragment being mRNA, the nucleic acid fragment comprising at least one of a first nucleic acid fragment, a second nucleic acid fragment and a third nucleic acid fragment; the first nucleic acid fragment encodes M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes S, Sec or SII protein of the feline infectious peritonitis virus; the first nucleic acid fragment, the second nucleic acid fragment and the third nucleic acid fragment are connected or not connected.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

The invention discloses a hybridoma cell strain for resisting porcine deltacoronavirus M protein, a monoclonal antibody and application of the monoclonal antibody, and belongs to the technical field of biology. The invention discloses a heavy chain variable region of a monoclonal antibody. The heavy chain variable region comprises a CDR1 of which the amino acid sequence is as shown in SEQ ID NO.5, a CDR2 of which the amino acid sequence is as shown in SEQ ID NO.6 and a CDR3 of which the amino acid sequence is as shown in SEQ ID NO.7; the light chain variable region comprises a CDR1 of which the amino acid sequence is as shown in SEQ ID NO.8, a CDR2 of which the amino acid sequence is as shown in SEQ ID NO.9 and a CDR3 of which the amino acid sequence is as shown in SEQ ID NO.10. The monoclonal antibody prepared by the invention can be used in laboratories and clinics, and lays an important foundation for clinical detection of PDCoV and research of pathogenic mechanism of PDCoV.

The invention discloses an anti-metapneumovirus M protein antibody and a derivative product and application thereof, the antibody is 7D4 or 5B8 and has high affinity and specificity to metapneumovirus M protein, and the derivative product comprises a detection reagent, a detection kit, a detection chip, a detection test strip and the like. The invention provides a new thought and strategy for early diagnosis or screening of metapneumovirus infection diseases.

Disclosed is a method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug. Specifically, the method includes the following steps: treating the tumor by using the recombinant oncolytic virus in combination with the small-molecule anticancer drug, wherein the small-molecule anticancer drug includes a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4 / 6, and a small-molecule anticancer drug targeting KRAS; and the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein after site-directed mutagenesis.

The present application relates to the technical field of biomedicine, and in particular to a method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug. Specifically, the method comprises the following steps: treating a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug, wherein the small-molecule anticancer drug includes a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4 / 6, and a small-molecule anticancer drug targeting KRAS; and the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein after site-directed mutagenesis. According to the present application, the recombinant oncolytic virus and the small-molecule anticancer drug are used in combination to attack and kill tumor cells, thereby achieving the synergistic efficacy.

This disclosure relates to the development of a multi-antigen mRNA vaccine against feline infectious peritonitis virus (FIPV). Provided is a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is mRNA and includes at least one of a first nucleic acid fragment, a second nucleic acid fragment, or a third nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes an S protein, an S_ec protein, or an SII protein of feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment, and the third nucleic acid fragment are linked or not linked.

The invention discloses a metapneumovirus M protein antibody and application thereof. The amino acid sequences of the complementary determining regions of the heavy chain variable region and the light chain variable region of the metapneumovirus M protein antibody provided by the invention are clear and are respectively shown as SEQ ID NO: 1-8, and the metapneumovirus M protein antibody has relatively high affinity and specificity to the metapneumovirus M protein. The metapneumovirus M protein antibody disclosed by the invention can effectively avoid cross reaction and remarkably improve the accuracy and sensitivity of detection, is suitable for early antigen detection of metapneumovirus infection, provides a reliable technical means for screening of metapneumovirus and prevention and control of diseases, and has a wide clinical application prospect.

Provided herein are engineered MHC molecules compositions for treatment of a disease or disorder. The compositions described herein include an engineered MHC heavy chain; an engineered beta 2-microglobulin (B2m) protein; and / or an MHC class I molecule complex that have been modified to have increased binding affinity to cell coreceptors, such as CD8, and also have increased internalization in immune cells relative to an otherwise comparable MHC class I heavy chain, B2m protein, or MHC class I molecule complex. Various protein constructs and pharmaceutical compositions of the engineered MHC molecules are provided. Methods of utilizing the protein constructs and pharmaceutical compositions of the modified MHC molecules are also provided.

Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.

The application provides a method for soluble expression and purification of recombinant human interleukin-2 or / and mutants thereof in a prokaryotic system, which utilizes a method for tandem fusion of two or more Sumo sequences, realizes soluble expression of human IL-2 in an E. coli expression system, avoids formation of inclusion bodies of IL-2 expressed by a traditional E. coli system, avoids expression of IL-2 and IL-2M in the form of inclusion bodies without structure and activity, avoids a process of IL-2 protein renaturation in the downstream, and realizes efficient purification of rhIL-2 and IL-2M proteins from a complex bacterial broken supernatant system through a simple chromatography step. The method has the characteristics of simple operation, suitability for scale-up, short cycle, high purity, stable process and the like.

The invention discloses a biomarker related to aortic dissection, a kit, a system and application thereof, and relates to the technical field of biological medicine. The biological marker related to the aortic dissection comprises a second biological marker; the second biomarker is used for predicting the clinical death risk of aortic dissection patients, and the second biomarker comprises SYTL1 protein, B2M protein, LYVE1 protein, TTR protein, PRSS2 protein, CSTF1 protein and H2BC5 protein. The plasma-based protein biomarker capable of predicting the mortality risk of the aortic dissection patient is successfully screened out, the pathogenesis of the disease can be explored easily, and the method has important significance on efficient, accurate and low-cost diagnosis of the aortic dissection patient.

The present invention is a hybridoma cell line for secreting monoclonal antibody against rabies virus M protein and its application, relates to the field of biotechnology. A classification of the hybridoma cell line is named as hybridoma cell line 4A1, and the hybridoma cell line was deposited on Apr. 1, 2019 in the China Center for Type Culture Collection, Wuhan University, Wuhan, China, with a deposit number CCTCC NO: C201947. The monoclonal antibody prepared by the hybridoma cell line has high titer, good specificity and excellent biological characteristics. The present invention identifies the variant antigen epitope recognized by the RABV M protein, the hybridoma cell line can be used to distinguish Flury strain and other RABV strains, prepare kit for detecting rabies virus RABV, detect RABV infection and differential diagnosis vaccine Flury strain and other RABV strains.

A pheromonicin against SARS-COV-2. Antibody mimetics, i.e., two 28-residues are designed for the first time by selecting the E protein and M protein of SARS-COV-2, which are relatively conserved and have low probability of mutation, as targets. Pharmacodynamic experiments performed using three SARS-COV-2 strains (the epidemic strain GD108, the South Africa strain SA and the India strain IND) respectively prove that fusion proteins obtained by linking the 28-residues to colicin can provide effective protective efficacy against pulmonary lesions induced by SARS-COV-2, and can be used as drugs for treating and preventing SARS-COV-2.

The invention relates to the technical field of veterinary biological products, and discloses a porcine reproductive and respiratory syndrome virus (PRRSV) genetic engineering subunit vaccine and a preparation method and application thereof, the vaccine comprises a PRRSV ZJ266 GP5-M protein complex and an adjuvant, and the adjuvant is a mannose modified chitosan solution. The PRRSV ZJ266 GP5-M protein compound is formed by GP5 protein and M protein of a PRRSV ZJ266 strain expressed and purified by a Bac-to-Bac baculovirus expression system, the nucleotide sequence of the PRRSV ZJ266 GP5-M protein compound is shown as SEQ ID NO: 1, and the amino acid sequence of the PRRSV ZJ266 GP5-M protein compound is shown as SEQ ID NO: 2. According to the invention, a high-level neutralizing antibody can be induced to generate, 100% protection is provided for attack of PRRSV NADC30-like virulent strains, the virus load can be significantly reduced, and detoxification can be prevented. The vaccine provided by the invention is safe and effective, the preparation process is stable, and a new high-quality product choice is provided for preventing the PRRSV.

The present invention provides immunomodulators for enhancing RNA expression, improving RNA stability, and / or prolonging RNA expression time. The invention provides a composition and application thereof. The composition comprises one or more immunomodulatory factors or active variants thereof, wherein the immunomodulatory factors are selected from the group consisting of ORF6, M protein, A46R, SOCS1, SOCS2, SOCS3, NSP5, NS5A, VP35, NS4b, tat, DHX58, B18R, V protein, VP3 and NS1; or a polynucleotide encoding the same; or a vector comprising a polynucleotide encoding the same.

This invention relates to the field of biotechnology, and particularly to a PRRSV-GP3-GP5-M+PCV2-TBCap recombinant protein, a vaccine, and its applications. This invention successfully expresses PRRSV GP5, GP3, and M proteins and PCV2TBCap protein using a cyclovir expression system. This recombinant protein can induce a favorable humoral and cellular immune response in the body, exhibiting good immunogenicity and safety.

Disclosed are compositions and methods for vaccinating susceptible individuals against infection by respiratory syncytial virus (RSV). The disclosed compositions include vaccine compositions comprising an effective amount of respiratory syncytial virus (RSV) F protein in a pre-fusion stabilized form and / or M protein incorporated into biodegradable polyanhydride polymer particles for inducing an immune response against RSV. The vaccine compositions also may include a suitable adjuvant.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to fusion protein and nanoparticles of porcine reproductive and respiratory syndrome virus recombinant epitopes and application of the fusion protein and the nanoparticles. A GP3 protein antigen epitope, a GP4 protein antigen epitope, a GP5 protein antigen epitope and an M protein antigen epitope are recombined, the obtained recombinant protein is closely related to protective immunity of the PRRSV, a strong humoral immune response aiming at the PRRSV can be generated after piglets are immunized, and a good protection effect is generated on infection of the PRRSV. The fusion protein is connected with the beta-cyclopeptide, and the beta-cyclopeptide serving as a nano skeleton can spontaneously form 24-surface nanoparticles, so that the antigen can be effectively presented, and the immune effect of the vaccine is promoted. Furthermore, the N terminal of the beta cyclopeptide is connected with an OX40L protein, and the OX40L protein belongs to a tumor necrosis factor ligand superfamily, so that the cellular immune effect can be further improved.